<DOC>
	<DOCNO>NCT00697216</DOCNO>
	<brief_summary>This study evaluate safety immunogenicity candidate HBV-MPL vaccine administer healthy adult age 15 40 year , accord 0 , 6- month vaccination schedule , Engerix™-B control administer 0 , 1 , 6 month .</brief_summary>
	<brief_title>Immunogenicity Safety GSK Biologicals ' HBV-MPL Vaccine Engerix™-B Healthy Adults ( 15-40 Yrs ) .</brief_title>
	<detailed_description>At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age : 15 40 year old . Good physical condition establish clinical examination history take time entry . Female participant risk become pregnant contraceptive programme necessary study period . Written inform consent obtain subject age 18 40 parents/tutor subject age 15 17 year . Positive titre screen antiHBs antibody . Elevated serum liver enzymes . History significant persisting hematologic , hepatic , renal , cardiac respiratory disease . Any acute disease moment entry . Chronic alcohol consumption . Hepatomegaly , right upper quadrant abdominal pain tenderness . Any chronic drug treatment , include treatment immunosuppressive drug , investigator 's opinion , preclude inclusion study . History allergic disease likely stimulate component vaccine . Simultaneous participation clinical trial . Previous vaccination hepatitis B vaccine . Previous vaccination MPL contain vaccine . Administration immunoglobulins past 6 month whole study period Simultaneous vaccination one week one week dose study vaccine</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Recombinant hepatitis B vaccine</keyword>
	<keyword>Adjuvanted hepatitis B vaccine</keyword>
</DOC>